{"id":4031,"date":"2017-09-22T12:22:29","date_gmt":"2017-09-22T12:22:29","guid":{"rendered":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=4031"},"modified":"2017-09-22T12:22:29","modified_gmt":"2017-09-22T12:22:29","slug":"leserbrief-nochmals-perioperatives-heparin-bridging","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/","title":{"rendered":"Leserbrief: Nochmals: Perioperatives Heparin-Bridging"},"content":{"rendered":"<p>\u00a0AMB 2017, 51, 71b\u00a0 Leserbrief: Nochmals: Perioperatives Heparin-Bridging (Erg\u00e4nzung und Korrektur) Antwort:&gt;&gt; Es herrscht auf dem Gebiet des Bridging tats\u00e4chlich sehr viel Unklarheit \u2013 und dies nicht erst seit der Einf\u00fchrung der neuen oralen Antikoagulanzien (NOAK). Der von uns in Grundz\u00fcgen zitierte Expertenkonsens des American College of Cardiology (ACC) gibt f\u00fcr die Behandlung von Patienten [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0AMB 2017, 51, 71b\u00a0 Leserbrief: Nochmals: Perioperatives Heparin-Bridging (Erg\u00e4nzung und Korrektur) Antwort:&gt;&gt; Es herrscht auf dem Gebiet des Bridging tats\u00e4chlich sehr viel Unklarheit \u2013 und dies nicht erst seit der Einf\u00fchrung der neuen oralen Antikoagulanzien (NOAK). Der von uns in Grundz\u00fcgen zitierte Expertenkonsens des American College of Cardiology (ACC) gibt f\u00fcr die Behandlung von Patienten [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[200,66,67,2123,2172,1564,780,121,61,323,122,60,203,204,205],"class_list":["post-4031","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-antikoagulanzien","tag-apoplektischer-insult","tag-arrhythmien","tag-bridge-studie","tag-bridging","tag-heparin","tag-herzrhythmusstoerungen","tag-hirninfarkt","tag-phenprocoumon","tag-rhythmusstoerungen","tag-schlaganfall","tag-thromboembolie","tag-vorhofflimmern","tag-warfarin"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Effektivit\u00e4t hitzestabilen kosteng\u00fcnstigen Rotavirus-Impfstoffs<\/title>\n<meta name=\"description\" content=\"Effektivit\u00e4t eines oralen hitzestabilen und kosteng\u00fcnstigen Rotavirus-Impfstoffs im Niger. Lesen Sie hier den gesamten Beitrage der abonnieren Sie diesen Artikel\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Effektivit\u00e4t hitzestabilen kosteng\u00fcnstigen Rotavirus-Impfstoffs\" \/>\n<meta property=\"og:description\" content=\"Effektivit\u00e4t eines oralen hitzestabilen und kosteng\u00fcnstigen Rotavirus-Impfstoffs im Niger. Lesen Sie hier den gesamten Beitrage der abonnieren Sie diesen Artikel\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-22T12:22:29+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-nochmals-perioperatives-heparin-bridging\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-nochmals-perioperatives-heparin-bridging\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Leserbrief: Nochmals: Perioperatives Heparin-Bridging\",\"datePublished\":\"2017-09-22T12:22:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-nochmals-perioperatives-heparin-bridging\\\/\"},\"wordCount\":187,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-nochmals-perioperatives-heparin-bridging\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"Absolute Arrhythmie\",\"Antikoagulanzien\",\"Apoplektischer Insult\",\"Arrhythmien\",\"BRIDGE-Studie\",\"Bridging\",\"Heparin\",\"Herzrhythmusst\u00f6rungen\",\"Hirninfarkt\",\"Phenprocoumon\",\"Rhythmusst\u00f6rungen\",\"Schlaganfall\",\"Thromboembolie\",\"Vorhofflimmern\",\"Warfarin\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-nochmals-perioperatives-heparin-bridging\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-nochmals-perioperatives-heparin-bridging\\\/\",\"name\":\"Effektivit\u00e4t hitzestabilen kosteng\u00fcnstigen Rotavirus-Impfstoffs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-nochmals-perioperatives-heparin-bridging\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-nochmals-perioperatives-heparin-bridging\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2017-09-22T12:22:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Effektivit\u00e4t eines oralen hitzestabilen und kosteng\u00fcnstigen Rotavirus-Impfstoffs im Niger. Lesen Sie hier den gesamten Beitrage der abonnieren Sie diesen Artikel\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-nochmals-perioperatives-heparin-bridging\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-nochmals-perioperatives-heparin-bridging\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-nochmals-perioperatives-heparin-bridging\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-nochmals-perioperatives-heparin-bridging\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leserbrief: Nochmals: Perioperatives Heparin-Bridging\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Effektivit\u00e4t hitzestabilen kosteng\u00fcnstigen Rotavirus-Impfstoffs","description":"Effektivit\u00e4t eines oralen hitzestabilen und kosteng\u00fcnstigen Rotavirus-Impfstoffs im Niger. Lesen Sie hier den gesamten Beitrage der abonnieren Sie diesen Artikel","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/","og_locale":"de_DE","og_type":"article","og_title":"Effektivit\u00e4t hitzestabilen kosteng\u00fcnstigen Rotavirus-Impfstoffs","og_description":"Effektivit\u00e4t eines oralen hitzestabilen und kosteng\u00fcnstigen Rotavirus-Impfstoffs im Niger. Lesen Sie hier den gesamten Beitrage der abonnieren Sie diesen Artikel","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2017-09-22T12:22:29+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Leserbrief: Nochmals: Perioperatives Heparin-Bridging","datePublished":"2017-09-22T12:22:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/"},"wordCount":187,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["Absolute Arrhythmie","Antikoagulanzien","Apoplektischer Insult","Arrhythmien","BRIDGE-Studie","Bridging","Heparin","Herzrhythmusst\u00f6rungen","Hirninfarkt","Phenprocoumon","Rhythmusst\u00f6rungen","Schlaganfall","Thromboembolie","Vorhofflimmern","Warfarin"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/","name":"Effektivit\u00e4t hitzestabilen kosteng\u00fcnstigen Rotavirus-Impfstoffs","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2017-09-22T12:22:29+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Effektivit\u00e4t eines oralen hitzestabilen und kosteng\u00fcnstigen Rotavirus-Impfstoffs im Niger. Lesen Sie hier den gesamten Beitrage der abonnieren Sie diesen Artikel","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-nochmals-perioperatives-heparin-bridging\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Leserbrief: Nochmals: Perioperatives Heparin-Bridging"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/4031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=4031"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/4031\/revisions"}],"predecessor-version":[{"id":4032,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/4031\/revisions\/4032"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=4031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=4031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=4031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}